Apheresis Breakthrough Targets Severe Preeclampsia, May Prolong Pregnancies

A recent news report from the European Medical Journal (EMJ) highlights a novel apheresis approach designed to target severe preeclampsia, a life-threatening pregnancy complication. This innovative treatment aims to specifically remove soluble Fms-like tyrosine kinase-1 (sFlt-1), a placental protein implicated in the pathogenesis of preeclampsia. The findings, derived from a single-arm open-label trial, suggest that sFlt-1 apheresis is safe, well-tolerated, and capable of reducing circulating sFlt-1 levels in women with very preterm preeclampsia. Preeclampsia is a complex hypertensive disorder that typically arises after 20 weeks of gestation, characterized by high blood pressure and signs of damage to other organ systems, most often the liver and kidneys. Globally, it complicates 2–8% of pregnancies and is a leading cause of maternal and perinatal mortality and morbidity. In India, hypertensive disorders of pregnancy affect approximately 11% of pregnant women, with the incidence of preeclampsia ranging from 5% to 10% of pregnancies. It contributes significantly to maternal deaths and fetal losses annually. Current medical treatments for preeclampsia primarily manage symptoms like high blood pressure and prevent seizures (e.g., with labetalol or magnesium sulfate), but the only definitive cure remains the delivery of the baby. This often necessitates premature birth, transferring morbidity risk to the neonate. In preeclampsia, the placenta produces an excess of sFlt-1, an antiangiogenic protein that binds to and inactivates essential growth factors like vascular endothelial growth factor (VEGF). This imbalance leads to widespread endothelial dysfunction, impacting blood vessels in crucial organs such as the kidneys, liver, and brain, and manifesting as the symptoms of preeclampsia. The novel apheresis approach detailed in the EMJ report utilizes an extracorporeal filtration strategy, akin to kidney dialysis, to selectively remove sFlt-1 from the mother's blood. Researchers developed an adsorber containing high-affinity IgG1 antibodies specifically directed against sFlt-1 to achieve this targeted removal, leaving other vital blood components intact. Preclinical studies in pregnant baboons demonstrated that this intervention could reduce circulating sFlt-1 levels by approximately 50%. Subsequent evaluation in women with very preterm preeclampsia, in a study that included both single and repeated dosing phases, showed promising results. Maternal and fetal vital signs remained stable, and individual apheresis sessions reduced circulating sFlt-1 levels by an average of 16.7% and mean arterial pressure by 4.1 mmHg. These findings are corroborated by studies published in Nature Medicine and reported by Cedars-Sinai, which highlight similar pilot results. These reports indicate that the blood filtering treatment safely lowered sFlt-1 levels and reduced high blood pressure. Crucially, in women who received multiple cycles of apheresis, pregnancy was extended for a median of 10 days after hospital admission, compared to 4 days for untreated women. Another pilot study published in the Journal of the American Society of Nephrology (JASN) also showed that apheresis could reduce sFlt-1 concentrations by about 18% and potentially delay delivery by 8 to 15 days compared to an untreated group's 3-day delay. The ability to safely prolong pregnancy, even by a few days or weeks, is clinically significant, especially for very preterm infants, as it can substantially improve neonatal outcomes and reduce the burden of intensive care. The relevance of this research to an Indian audience is substantial. Preeclampsia is a significant public health challenge in India, with high prevalence rates and a considerable contribution to maternal and perinatal morbidity and mortality. The ability to delay delivery safely could drastically impact neonatal survival and health in a country where access to advanced neonatal intensive care might be limited in certain regions. The Government of India is aware of the increasing cases of preeclampsia and is promoting awareness, early detection, and improved maternal care through various initiatives under the National Health Mission (NHM), including regular screening and educational programs. A novel treatment like targeted apheresis could complement these efforts by providing a therapeutic intervention where currently none exists, offering a chance to extend pregnancies and allow for more fetal development before birth. However, it is crucial to note that these are early-stage findings from pilot and single-arm open-label trials. While the results are encouraging and suggest safety and tolerability, larger, randomized controlled trials are warranted and essential to confirm the efficacy, optimize treatment protocols, and establish the broader clinical applicability of this novel apheresis approach. Despite these limitations, the targeted apheresis approach represents a significant step forward in the quest for disease-specific therapies for severe preeclampsia, offering hope for improved maternal and neonatal outcomes worldwide.

Frequently Asked Questions

Read Full Story on Quick Digest